Abstract:Context - MicroRNAs (miRNAs) represent a class of small non-coding RNAs that regulate the gene expressions at the posttranscriptional level, subsequently control crucial physiological processes. Recent evidence demonstrates that some miRNAs have the functions similar to oncogene or tumor suppressors, It may play important roles in tumorigenesis MiRNA expression profiles may become useful biomarkers for cancer diagnostics, prognosis and prediction of response to treatment, and it could be a powerful tool for cancer prevention and therapeuticsObjective - To explore the global expression profile of miRNAs in non small cell lung cancer (NSCLC) and its potential relevance to clinicopathological characteristics and prognosis.Methods. - LNA microRNA microarrays were utilized to detect miRNA expression levels in eight surgically removed lung carcinoma tissues (La) and their corresponding normal lung tissues (NT) After initial microarray validation by quantitative real-time reverse transcription polymerase chain reaction assays (qRT-PCR), miR-21, miR-143 and miR-181a were selected for further study in another 47 paired LCTs and matched NTs by qRT-PCR using Taqman microRNA assay.Results. - Twenty-seven microRNAs were observed to be deregulated greater than two-fold in LCT compared with NT by microarray. Consistenting with the microarray, the expression level of miR-21 by qRT-PCR was significantly higher in tumor tissues than in adjacent normal tissues (P = 0026); while miR-143 (P = 0.000) and miR-181a (P= 0.000) were downregulated in LCT. Interestingly, among the 47 NSCLC cases, low level expression of miR-143 was significantly correlated with smoking status (P= 0026), high miR-21 expression (hazard ratio, 5993, 95% confidence interval, 2 518-14.264; P= 0.000) and low miR-181a expression (hazard ratio, 0.328, 95% confidence interval 0.142-0 756; P = 0.009) were associated with poor survival, independent of clinical covariates. including TNM staging, lymph note status.Conclusion. - Our data thus indicating the potential of miR-21, miR-143 and miR-181a as a novel diagnostic or prognostic biomarker for NSCLC. Besides, these data will guide further studies of specific microRNAs might become potential targets for therapeutic intervention. (C) 2010 Elsevier Masson SAS All rights reserved.

Research Progress on Lung Cancer Related MicroRNAs

Molecular Mechanisms and Clinical Applications of Mir-22 in Regulating Malignant Progression in Human Cancer (Review)

Research progress on the relationship between lung cancer drug-resistance and microRNAs

Research Progress on Lung Cancer Therapy and the Mechanism of MicroRNA in Lung Cancer and Its Drug Resistance

Advances of Microrna in Lung Cancer

Progress of the Studies on Relationship Between MicroRNAs and Lung Cancer

Tumor Suppressor Mir-22 Suppresses Lung Cancer Cell Progression Through Post-Transcriptional Regulation of Erbb3

Roles of Microrna in Diagnosis, Therapy and Prognosis of Lung Cancer

MicroRNA Expression Profiles Predict Progression and Clinical Outcome in Lung Adenocarcinoma

MicroRNA-targeted therapeutics for lung cancer treatment

Systematic analysis reveals key microRNAs as diagnostic and prognostic factors in progressive stages of lung cancer

MiRNA-based therapeutic strategy in lung cancer.

In-depth Bioinformatic Analysis of Lung Cancer-Associated Microrna Targets

Multidimensional Communication of Micrornas and Long Non-Coding RNAs in Lung Cancer

Research progress on WNT/β-catenin signaling pathway and miRNA in primary lung cancer

Progress on the Relationship Between Mirna and Lung Cancer in Radiosensitivity

Deregulated Expression of Mir-21, Mir-143 and Mir-181A in Non Small Cell Lung Cancer is Related to Clinicopathologic Characteristics or Patient Prognosis

Comprehensive Analysis of Hsa-Mir-654-5p's Tumor-Suppressing Functions

Correction: Non-small-cell Lung Cancer and Mirnas: Novel Biomarkers and Promising Tools for Treatment

Involvement of Micrornas in Lung Cancer Biology and Therapy

MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer